Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.36 |
| ▸ | SCD | O00767 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598928 | 0.93 | TRPC6 (0.42) | IKBKBCHUKTRPC6SCDPOLB | |
| SCHEMBL22834868 | 0.93 | TRPC6 (0.42) | IKBKBCHUKTRPC6SCDPOLB | |
| SCHEMBL22834682 | 0.93 | TRPC6 (0.40) | IKBKBCHUKFEN1TRPC6SCD | |
| SCHEMBL26598674 | 0.79 | IKBKB (0.38) | IKBKBCHUKSCDPOLB | |
| SCHEMBL30606154 | 0.79 | IKBKB (0.38) | IKBKBCHUKSCDPOLB | |
| SCHEMBL21011635 | 0.75 | TBK1 (0.39) | FEN1TRPC6 | |
| SCHEMBL29951840 | 0.75 | POLB (0.42) | FEN1TRPC6POLBMCHR1ALOX5AP | |
| SCHEMBL15527772 | 0.74 | LMNA (0.41) | TRPC6POLBNOS3NOS1NOS2 | |
| SCHEMBL22235746 | 0.73 | CDK2 (0.46) | FEN1TRPC6MCHR1ALOX5APNOS3 | |
| SCHEMBL22834443 | 0.73 | TRPC6 (0.45) | FEN1TRPC6ALOX5APNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267576-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3786160-A1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10889568-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| WO-2020263980-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3700902-A1 | PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | IKBKB 1420/4885CHUK 662/4885FEN1 4664/4885 |
| US-10889568-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | IKBKB 1420/4885CHUK 662/4885FEN1 4664/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | IKBKB 1420/4885CHUK 662/4885FEN1 4664/4885 |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK1, IRAK2 | IKBKB 10/4885CHUK 15/4885FEN1 2222/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | IKBKB 20/4885CHUK 39/4885FEN1 2568/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | IKBKB 1420/4885CHUK 662/4885FEN1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.